Healthcare provider profile · identity verified

Peter Henry Germscheid, M.D.

Family Practice · LITTLE FALLS, MN · NPI 1679505267

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	550	138
Lisinopril	Lisinopril	252	67
Metformin Hcl	Metformin Hcl	227	59
Simvastatin	Simvastatin	215	53
Tamsulosin Hcl	Tamsulosin Hcl	202	53
Omeprazole	Omeprazole	199	47
Amlodipine Besylate	Amlodipine Besylate	189	51
Metoprolol Succinate	Metoprolol Succinate	181	49
Losartan Potassium	Losartan Potassium	156	45
Levothyroxine Sodium	Levothyroxine Sodium	143	34
Furosemide	Furosemide	140	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	116	29
Hydrochlorothiazide	Hydrochlorothiazide	115	33
Metoprolol Tartrate	Metoprolol Tartrate	102	25
Clopidogrel	Clopidogrel Bisulfate	98	24
Gabapentin	Gabapentin	95	26
Rosuvastatin Calcium	Rosuvastatin Calcium	92	28
Carvedilol	Carvedilol	84	25
Potassium Chloride	Potassium Chloride	84	21
Tramadol Hcl	Tramadol Hcl	84	16
Allopurinol	Allopurinol	83	18
Pravastatin Sodium	Pravastatin Sodium	81	25
Albuterol Sulfate Hfa	Albuterol Sulfate	79	27
Spironolactone	Spironolactone	73	16
Terazosin Hcl	Terazosin Hcl	70	19
Warfarin Sodium	Warfarin Sodium	70	14
Xarelto	Rivaroxaban	66	13
Famotidine	Famotidine	63	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	63	12
Pantoprazole Sodium	Pantoprazole Sodium	63	23
Metformin Hcl Er	Metformin Hcl	61	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	59	20
Fluticasone Propionate	Fluticasone Propionate	59	16
Mirtazapine	Mirtazapine	59	14
Sertraline Hcl	Sertraline Hcl	59	13
Pioglitazone Hcl	Pioglitazone Hcl	55	15
Lorazepam	Lorazepam	54	suppressed
Eliquis	Apixaban	53	13
Tradjenta	Linagliptin	53	13
Citalopram Hbr	Citalopram Hydrobromide	50	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	48	13
Clonidine Hcl	Clonidine Hcl	45	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	45	11
Movantik	Naloxegol Oxalate	44	suppressed
Trazodone Hcl	Trazodone Hcl	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	12
Myrbetriq	Mirabegron	42	suppressed
Ozempic	Semaglutide	42	suppressed
Finasteride	Finasteride	40	16
Triamcinolone Acetonide	Triamcinolone Acetonide	40	22
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Valsartan	Valsartan	39	12
Ondansetron Hcl	Ondansetron Hcl	38	suppressed
Prednisone	Prednisone	38	25
Jardiance	Empagliflozin	37	11
Atenolol	Atenolol	36	suppressed
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Meloxicam	Meloxicam	34	13
Memantine Hcl	Memantine Hcl	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Glipizide Er	Glipizide	30	suppressed
Risperidone	Risperidone	29	suppressed
Farxiga	Dapagliflozin Propanediol	28	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Ventolin Hfa	Albuterol Sulfate	26	12
Spiriva Handihaler	Tiotropium Bromide	25	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	23	suppressed
Glimepiride	Glimepiride	23	suppressed
Morphine Sulfate Er	Morphine Sulfate	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Dutasteride	Dutasteride	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	19	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Nabumetone	Nabumetone	15	suppressed
Trulicity	Dulaglutide	15	suppressed
Baclofen	Baclofen	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Lurasidone Hcl	Lurasidone Hcl	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Lithium Carbonate	Lithium Carbonate	13	suppressed
Mesalamine	Mesalamine	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Constulose	Lactulose	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error